We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+36.28%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
+$257M
Cap. Flow
+$20M
Cap. Flow %
1.75%
Top 10 Hldgs %
86.4%
Holding
27
New
2
Increased
4
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$74.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$9.85M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.73M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.02M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.81M

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$56M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$14.4M
3
TPST icon
Tempest Therapeutics
TPST
+$7.37M
4
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$319M 28%
10,542,790
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$192M 16.84%
5,827,415
-1,456,854
-20% -$56M
PASG icon
3
Passage Bio
PASG
$13.9M
$137M 12.02%
250,461
– –
PCVX icon
4
Vaxcyte
PCVX
$9.1B
$73M 6.41%
+2,309,554
New +$74.3M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.08B
$69.4M 6.1%
3,566,912
– –
ANAB icon
6
AnaptysBio
ANAB
$1.7B
$51.7M 4.54%
2,316,447
– –
TBIO
7
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$39.1M 3.43%
2,182,789
– –
KRYS icon
8
Krystal Biotech
KRYS
$10.6B
$37.1M 3.26%
895,000
– –
IOVA icon
9
Iovance Biotherapeutics
IOVA
$3.74B
$36M 3.16%
1,312,999
-437,666
-25% -$14.4M
ADVM
10
DELISTED
Adverum Biotechnologies
ADVM
$30M 2.63%
143,703
+15,870
+12% +$2.81M
ALPN
11
DELISTED
Alpine Immune Sciences Inc
ALPN
$25M 2.19%
2,571,450
– –
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$22.3M 1.96%
2,755,000
+311,191
+13% +$1.93M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.8B
$19.6M 1.72%
1,320,045
+329,334
+33% +$5.02M
COLL icon
14
Collegium Pharmaceutical
COLL
$820M
$16.5M 1.45%
943,666
– –
GRTS
15
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.7M 1.2%
2,061,758
– –
APTX
16
DELISTED
Aptinyx Inc. Common Stock
APTX
$13.3M 1.17%
3,190,079
– –
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.1M 1.06%
+2,364,500
New +$9.85M
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$397M
$11.1M 0.97%
528,000
+318,000
+151% +$5.73M
ALNA
19
DELISTED
Allena Pharmaceuticals
ALNA
$5.26M 0.46%
3,330,373
– –
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
$4.84M 0.43%
65,613
– –
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.87M 0.25%
17,026
– –
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.45M 0.22%
202,803
– –
VTVT icon
23
vTv Therapeutics
VTVT
$130M
$2.39M 0.21%
26,550
– –
ITRM
24
DELISTED
Iterum Therapeutics
ITRM
$1.83M 0.16%
102,554
– –
ETTX
25
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$1.04M 0.09%
349,953
-700,000
-67% -$1.91M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q2 2020 Portfolio in Review

As of Q2 2020, Frazier Management held 27 positions worth $1.14B, up 29% from $882M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Frazier Management's Q2 2020 filing shows 2 new, 4 increased, 3 reduced and 1 closed positions. Its largest new stake was Vaxcyte: 2,309,554 shares worth $73M. The largest sale was Phathom Pharmaceuticals, an estimated $56M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Frazier Management's largest Q2 2020 buy was Vaxcyte: 2,309,554 shares worth $73M.
  • Frazier Management added most to Rocket Pharmaceuticals in Q2 2020, an estimated $5.73M increase.
  • Frazier Management's biggest Q2 2020 reduction was Phathom Pharmaceuticals, cutting an estimated $56M.
  • Frazier Management fully exited Tempest Therapeutics in Q2 2020, selling an estimated $7.37M.
  • Frazier Management's ten largest holdings make up 86% of its $1.14B portfolio in Q2 2020.
  • Frazier Management opened 2 new positions and closed 1 in Q2 2020.
  • Frazier Management's portfolio value rose 29% quarter-over-quarter to $1.14B.

Based on Frazier Management's 13F filing for Q2 2020, filed 4 Aug 2020.